Instituut voor Neuropathische Pijn
English articles Research & Development Perampanel from Eisai in neuropathic pain
| Perampanel from Eisai in neuropathic pain |
 Perampanel from Eisai, currently in phase II for neuropathic pain. E2007 (perampanel) is a orally administered, selective non-competitive AMPA-type glutamate receptor antagonist. Other development indications: Parkinson's disease, epilepsy, multiple sclerosis and migraine prophylaxis. In Parkinson's disease the drug failed. Information from 2008 related to neuropathic pain states that
a Phase II Proof of concept Study (#227) in painful diabetic neuropathy (PDN) completed enrollment in March 2008 and is expected to provide top-line results in September 2008; results have not yet been published. A Phase II study in post-herpetic neuralgia (PHN), was initiated in January 2008. [1] From the Centre for the study and treatment of Neuropathic Pain and Neuropathy in Soest, the NetherlandsThis site helps patients and treating physicians, neurologists, anesthesiologists and other pain specialists to find the best and most up to date research findings related to neuropathy and neuropathic pain and the treatment thereof. In our centre we are specialised in treating patients suffering from neuropathic pain and neuropathy following an Integrated Medicine concept. Part of our activities are within the field of consultation. We assist pharmaceutical companies in R&D strategies related to finding new drugs to treat neuropathic pain and neuropathy.
April 2010, Jan M. Keppel Hesselink, MD, PhD
Referenties[1]: Tomillero A, Moral MA. | Gateways to clinical trials. | Methods Find Exp Clin Pharmacol. | 2009 Mar;31(2):107-46. |